A Laios1, N Baharuddin1, K Iliou2, E Gubara1, G O'Sullivan3. 1. Department of Obstetrics and Gynaecology, University College Hospital Galway, Galway, Ireland. 2. Department of Anatomy-Histology-Embryology, Medical School, University of Ioannina, Greece. 3. Department of Interventional Radiology, University College Hospital Galway, Galway, Ireland.
Abstract
BACKGROUND: Uterine fibroids are the most common reproductive tract tumours in females. Uterine artery embolization (UAE) is a fertility-sparing procedure for treatment of symptomatic fibroids. We evaluated the efficacy and safety of UAE in the treatment of 118 patients with symptomatic uterine fibroids in a single Academic Centre in the West of Ireland to determine whether fibroid and uterine size affect clinical outcomes and complications. METHODS: This was a retrospective cohort of 118 patients who underwent UAE for treatment of symptomatic fibroids between November 2006 and August 2011. Diagnosis of fibroids in symptomatic patients was established by magnetic resonance imaging (MRI) and/or transabdominal ultrasonography (US). Three different embolic agents were used. All patients had at least one follow-up using MRI, at three and/or 12 months. A non-validated questionnaire was used to report patient satisfaction with regards to symptoms improvement on a yes-or-no basis. RESULTS: Mean fibroid volume, uterine size and dominant fibroid size were significantly reduced at three months and one year follow-up (p = 0.00) and that was tallied with symptoms improvement (p < 0.05). Overall patient satisfaction at three months was 84% falling to 75.9% by 12 months (all p < 0.05). Few complications were reported (2.5%). No significant difference was observed in safety or efficacy for different embolic agents. CONCLUSION: The study confirms the safety and efficacy of UAE in the treatment of symptomatic fibroids. Hippokratia 2014; 18 (3): 258-261.
BACKGROUND: Uterine fibroids are the most common reproductive tract tumours in females. Uterine artery embolization (UAE) is a fertility-sparing procedure for treatment of symptomatic fibroids. We evaluated the efficacy and safety of UAE in the treatment of 118 patients with symptomatic uterine fibroids in a single Academic Centre in the West of Ireland to determine whether fibroid and uterine size affect clinical outcomes and complications. METHODS: This was a retrospective cohort of 118 patients who underwent UAE for treatment of symptomatic fibroids between November 2006 and August 2011. Diagnosis of fibroids in symptomatic patients was established by magnetic resonance imaging (MRI) and/or transabdominal ultrasonography (US). Three different embolic agents were used. All patients had at least one follow-up using MRI, at three and/or 12 months. A non-validated questionnaire was used to report patient satisfaction with regards to symptoms improvement on a yes-or-no basis. RESULTS: Mean fibroid volume, uterine size and dominant fibroid size were significantly reduced at three months and one year follow-up (p = 0.00) and that was tallied with symptoms improvement (p < 0.05). Overall patient satisfaction at three months was 84% falling to 75.9% by 12 months (all p < 0.05). Few complications were reported (2.5%). No significant difference was observed in safety or efficacy for different embolic agents. CONCLUSION: The study confirms the safety and efficacy of UAE in the treatment of symptomatic fibroids. Hippokratia 2014; 18 (3): 258-261.
Authors: Richard D Edwards; Jonathan G Moss; Mary Ann Lumsden; Olivia Wu; Lilian S Murray; Sara Twaddle; Gordon D Murray Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: James B Spies; Curt Cornell; Robert Worthington-Kirsch; John C Lipman; James F Benenati Journal: J Vasc Interv Radiol Date: 2007-02 Impact factor: 3.464
Authors: Wouter J K Hehenkamp; Nicole A Volkers; Peter F J Donderwinkel; Sjoerd de Blok; Erwin Birnie; Willem M Ankum; Jim A Reekers Journal: Am J Obstet Gynecol Date: 2005-11 Impact factor: 8.661
Authors: Nicole A Volkers; Wouter J K Hehenkamp; Erwin Birnie; Willem M Ankum; Jim A Reekers Journal: Am J Obstet Gynecol Date: 2007-06 Impact factor: 8.661